Keynote is a series of clinical trials to determine whether an investigational immunotherapy may help in the treatment of cancer. The investigational immunotherapy is pembrolizumab (MK-3475).
Merck has investigational clinical trials under way or planned in multiple cancer types. We are currently studying the types of cancer listed below. We encourage you to speak with your physician to determine if a Keynote clinical trial may be right for you.
There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.